<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35454374</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1648-9144</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>13</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle>Late-Onset Hypogonadism in a Male Patient with Long COVID Diagnosed by Exclusion of ME/CFS.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">536</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina58040536</ELocationID><Abstract><AbstractText>After the acute phase of COVID-19, some patients have been reported to have persistent symptoms including general fatigue. We have established a COVID-19 aftercare clinic (CAC) to provide care for an increasing number of these patients. Here, we report the case of a 36-year-old man who developed post-COVID fatigue after acute infection with SARS-CoV-2. In the acute phase of COVID-19, the patient's fever resolved within four days; however, general fatigue persisted for three months, and he visited our CAC 99 days after the initial infection. Examination revealed a high Aging Male's Symptoms (AMS) score of 44 and low free testosterone (FT) level of 5.5 pg/mL, which meet the Japanese criteria of late-onset hypogonadism (LOH) syndrome. Imaging studies revealed an atrophic pituitary in addition to fatty liver and low bone mineral density. Anterior pituitary function tests showed a low follicle-stimulating hormonelevel and delayed reaction of luteinizing hormone (LH) after gonadotropin-releasing hormone (GnRH) stimulation, indicating the possibility of hypothalamic hypogonadism in addition to primary hypogonadism seen in patients with post-COVID-19 conditions. After the initiation of Japanese traditional medicine (Kampo medicine: hochuekkito followed by juzentaihoto), the patient's symptoms as well as his AMS score and serum FT level were noticeably improved. Furthermore, follow-up tests of GnRH stimulation revealed improvements in LH responsiveness. Although many patients have been reported to meet the criteria of ME/CFS such as our case, we emphasize the possibility of other underlying pathologies including LOH syndrome. In conclusion, LOH syndrome should be considered a cause of general fatigue in patients with post-COVID-19 conditions and herbal treatment might be effective for long COVID symptoms due to LOH (264 words).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soejima</LastName><ForeName>Yoshiaki</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-2070-3892</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6015-6128</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tokumasu</LastName><ForeName>Kazuki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakano</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9972-791X</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harada</LastName><ForeName>Ko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamoto</LastName><ForeName>Kenta</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sunada</LastName><ForeName>Naruhiko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakurada</LastName><ForeName>Yasue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Kou</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagiya</LastName><ForeName>Hideharu</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5086-1891</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ueda</LastName><ForeName>Keigo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Fumio</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-7014-9095</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>33515-09-2</RegistryNumber><NameOfSubstance UI="D007987">Gonadotropin-Releasing Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>3XMK78S47O</RegistryNumber><NameOfSubstance UI="D013739">Testosterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-67-9</RegistryNumber><NameOfSubstance UI="D007986">Luteinizing Hormone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="Y">Fatigue Syndrome, Chronic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007987" MajorTopicYN="N">Gonadotropin-Releasing Hormone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007006" MajorTopicYN="Y">Hypogonadism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007986" MajorTopicYN="N">Luteinizing Hormone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">free testosterone</Keyword><Keyword MajorTopicYN="N">general fatigue</Keyword><Keyword MajorTopicYN="N">late-onset hypogonadism</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-COVID condition</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>23</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35454374</ArticleId><ArticleId IdType="pmc">PMC9025899</ArticleId><ArticleId IdType="doi">10.3390/medicina58040536</ArticleId><ArticleId IdType="pii">medicina58040536</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Raveendran A.V., Jayadevan R., Sashidharan S. Long COVID: An overview. Diabetes Metab. Syndr. 2021;15:869&#x2013;875. doi: 10.1016/j.dsx.2021.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.04.007</ArticleId><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T., Hittle M., Goodman S.N. Assessment of the Frequency and Variety of Persistent Symptoms Among Patients with COVID-19: A Systematic Review. JAMA Netw. Open. 2021;4:e2111417. doi: 10.1001/jamanetworkopen.2021.11417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11417</ArticleId><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D., Sun A., Ssentongo A.E., Ba D.M., Parsons N., Poudel G.R., Lekoubou A., Oh J.S., Ericson J.E., Ssentongo P., et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. JAMA Netw. Open. 2021;4:e2128568. doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., Villapol S. More than 50 Long-term effects of COVID-19: A systematic review and meta-analysis. Sci. Rep. 2021;11:16144. doi: 10.1038/s41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A., Bernabei R., Landi F. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2021;22:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsuka Y., Tokumasu K., Nakano Y., Honda H., Sakurada Y., Sunada N., Omura D., Hasegawa K., Hagiya H., Obika M., et al. Clinical Characteristics of Japanese Patients Who Visited a COVID-19 Aftercare Clinic for Post-Acute Sequelae of COVID-19/Long COVID. Cureus. 2021;13:e18568. doi: 10.7759/cureus.18568.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.18568</ArticleId><ArticleId IdType="pmc">PMC8571943</ArticleId><ArticleId IdType="pubmed">34760415</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakurada Y., Sunada N., Honda H., Tokumasu K., Otsuka Y., Nakano Y., Hanayama Y., Furukawa M., Hagiya H., Otsuka F. Serial Changes of Long COVID Symptoms and Clinical Utility of Serum Antibody Titers for Evaluation of Long COVID. J. Clin. Med. 2022;11:1309. doi: 10.3390/jcm11051309.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11051309</ArticleId><ArticleId IdType="pmc">PMC8911256</ArticleId><ArticleId IdType="pubmed">35268400</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal R., Gubbi S., Koch C.A. COVID-19 and chronic fatigue syndrome: An endocrine perspective. J. Clin. Transl. Endocrinol. 2022;27:100284. doi: 10.1016/j.jcte.2021.100284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcte.2021.100284</ArticleId><ArticleId IdType="pmc">PMC8641402</ArticleId><ArticleId IdType="pubmed">34877261</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrott B., Head R., Pringle K.G., Lumbers E.R., Martin J.H. &#x201c;LONG COVID&#x201d;&#x2014;A hypothesis for understanding the biological basis and pharmacological treatment strategy. Pharmacol. Res. Perspect. 2022;10:e00911. doi: 10.1002/prp2.911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.911</ArticleId><ArticleId IdType="pmc">PMC8929332</ArticleId><ArticleId IdType="pubmed">35029046</ArticleId></ArticleIdList></Reference><Reference><Citation>Zung W.W. A SELF-RATING DEPRESSION SCALE. Arch. Gen. Psychiatry. 1965;12:63&#x2013;70. doi: 10.1001/archpsyc.1965.01720310065008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.1965.01720310065008</ArticleId><ArticleId IdType="pubmed">14221692</ArticleId></ArticleIdList></Reference><Reference><Citation>Daig I., Heinemann L.A., Kim S., Leungwattanakij S., Badia X., Myon E., Moore C., Saad F., Potthoff P., Thai do M. The Aging Males&#x2019; Symptoms (AMS) scale: Review of its methodological characteristics. Health Qual. Life Outcomes. 2003;1:77. doi: 10.1186/1477-7525-1-77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-1-77</ArticleId><ArticleId IdType="pmc">PMC317369</ArticleId><ArticleId IdType="pubmed">14675485</ArticleId></ArticleIdList></Reference><Reference><Citation>Namiki M., Akaza H., Shimazui T., Ito N., Iwamoto T., Baba K., Kumano H., Koh E., Tsujimura A., Matsumiya K., et al. Clinical practice manual for late-onset hypogonadism syndrome. Int. J. Urol. 2008;15:377&#x2013;388. doi: 10.1111/j.1442-2042.2008.02010.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1442-2042.2008.02010.x</ArticleId><ArticleId IdType="pubmed">18452452</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunenfeld B., Mskhalaya G., Zitzmann M., Corona G., Arver S., Kalinchenko S., Tishova Y., Morgentaler A. Recommendations on the diagnosis, treatment and monitoring of testosterone deficiency in men. Aging Male. 2021;24:119&#x2013;138. doi: 10.1080/13685538.2021.1962840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13685538.2021.1962840</ArticleId><ArticleId IdType="pubmed">34396893</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadihasanoglu M., Aktas S., Yardimci E., Aral H., Kadioglu A. SARS-CoV-2 Pneumonia Affects Male Reproductive Hormone Levels: A Prospective, Cohort Study. J. Sex. Med. 2021;18:256&#x2013;264. doi: 10.1016/j.jsxm.2020.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2020.11.007</ArticleId><ArticleId IdType="pmc">PMC7691132</ArticleId><ArticleId IdType="pubmed">33468445</ArticleId></ArticleIdList></Reference><Reference><Citation>Salonia A., Pontillo M., Capogrosso P., Gregori S., Tassara M., Boeri L., Carenzi C., Abbate C., Cignoli D., Ferrara A.M., et al. Severely low testosterone in males with COVID-19: A case-control study. Andrology. 2021;9:1043&#x2013;1052. doi: 10.1111/andr.12993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/andr.12993</ArticleId><ArticleId IdType="pmc">PMC8013327</ArticleId><ArticleId IdType="pubmed">33635589</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T.T., Hulme J., Tran H.D., Vo T.K., Vo G.V. The potential impact of COVID-19 on male reproductive health. J. Endocrinol. Investig. 2022:1&#x2013;13. doi: 10.1007/s40618-022-01764-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-022-01764-z</ArticleId><ArticleId IdType="pmc">PMC8856879</ArticleId><ArticleId IdType="pubmed">35181849</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta S., Sengupta P. SARS-CoV-2 and Male Infertility: Possible Multifaceted Pathology. Reprod. Sci. 2021;28:23&#x2013;26. doi: 10.1007/s43032-020-00261-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43032-020-00261-z</ArticleId><ArticleId IdType="pmc">PMC7351544</ArticleId><ArticleId IdType="pubmed">32651900</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X., Guan C., Chen R., Wang Y., Feng S., Wang R., Qu G., Zhao S., Wang F., Wang X., et al. Pathological and molecular examinations of postmortem testis biopsies reveal SARS-CoV-2 infection in the testis and spermatogenesis damage in COVID-19 patients. Cell. Mol. Immunol. 2021;18:487&#x2013;489. doi: 10.1038/s41423-020-00604-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00604-5</ArticleId><ArticleId IdType="pmc">PMC7734388</ArticleId><ArticleId IdType="pubmed">33318629</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta P., Dutta S. COVID-19 and hypogonadism: Secondary immune responses rule-over endocrine mechanisms. Hum. Fertil. 2021:1&#x2013;6. doi: 10.1080/14647273.2020.1867902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14647273.2020.1867902</ArticleId><ArticleId IdType="pubmed">33439057</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiloiro S., Giampietro A., Bianchi A., De Marinis L. Empty sella syndrome: Multiple endocrine disorders. Handb. Clin. Neurol. 2021;181:29&#x2013;40. doi: 10.1016/b978-0-12-820683-6.00003-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/b978-0-12-820683-6.00003-8</ArticleId><ArticleId IdType="pubmed">34238465</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers B.M., Jain A.K., De Meirleir K.L., Peterson D.L., Klimas N.G., Lerner A.M., Bested A.C., Flor-Henry P., Joshi P., Powles A.C.P., et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. J. Chronic Fatigue Syndr. 2003;11:7&#x2013;115. doi: 10.1300/J092v11n01_02.</Citation><ArticleIdList><ArticleId IdType="doi">10.1300/J092v11n01_02</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers B.M., van de Sande M.I., De Meirleir K.L., Klimas N.G., Broderick G., Mitchell T., Staines D., Powles A.C., Speight N., Vallings R., et al. Myalgic encephalomyelitis: International Consensus Criteria. J. Intern. Med. 2011;270:327&#x2013;338. doi: 10.1111/j.1365-2796.2011.02428.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2011.02428.x</ArticleId><ArticleId IdType="pmc">PMC3427890</ArticleId><ArticleId IdType="pubmed">21777306</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayton E.W. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: An IOM report on redefining an illness. JAMA. 2015;313:1101&#x2013;1102. doi: 10.1001/jama.2015.1346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.1346</ArticleId><ArticleId IdType="pubmed">25668027</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong S.J., Liu S. Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies. Rev. Med. Virol. 2021:e2315. doi: 10.1002/rmv.2315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2315</ArticleId><ArticleId IdType="pubmed">34888989</ArticleId></ArticleIdList></Reference><Reference><Citation>Simani L., Ramezani M., Darazam I.A., Sagharichi M., Aalipour M.A., Ghorbani F., Pakdaman H. Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. J. Neurovirol. 2021;27:154&#x2013;159. doi: 10.1007/s13365-021-00949-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-021-00949-1</ArticleId><ArticleId IdType="pmc">PMC7852482</ArticleId><ArticleId IdType="pubmed">33528827</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re&#x2019;em Y., Redfield S., Austin J.P., Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Hermosillo J.A., Mart&#xed;nez-L&#xf3;pez J.P., Carrillo-Lamp&#xf3;n S.A., Ruiz-Ojeda D., Herrera-Ram&#xed;rez S., Amezcua-Guerra L.M., Mart&#xed;nez-Alvarado M.D.R. Post-Acute COVID-19 Symptoms, a Potential Link with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A 6-Month Survey in a Mexican Cohort. Brain Sci. 2021;11:760. doi: 10.3390/brainsci11060760.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11060760</ArticleId><ArticleId IdType="pmc">PMC8227652</ArticleId><ArticleId IdType="pubmed">34201087</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi H., Okubo H. Clinical efficiency of combination therapy using testosterone replacement therapy, phosphodiesterase 5 inhibitors and Kampo herbal medicine for eugonadal patients with late-onset hypogonadism syndrome. Exp. Ther. Med. 2021;22:1173. doi: 10.3892/etm.2021.10608.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2021.10608</ArticleId><ArticleId IdType="pmc">PMC8393732</ArticleId><ArticleId IdType="pubmed">34504618</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumamoto T., Hisasue S., Yasuda M., Ide H., China T., Inoue M., Saito K., Isotani S., Yamaguchi R., Muto S., et al. Hochuekkito Efficacy in Late-Onset Hypogonadism (LOH) patients. Kampo Med. 2013;64:160&#x2013;165. doi: 10.3937/kampomed.64.160.</Citation><ArticleIdList><ArticleId IdType="doi">10.3937/kampomed.64.160</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito S., Manabe E., Dai Y., Ishihara M., Tsujino T. Juzentaihoto improves adenine-induced chronic renal failure in BALB/c mice via suppression of renal fibrosis and inflammation. J. Pharmacol. Sci. 2022;148:172&#x2013;178. doi: 10.1016/j.jphs.2021.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphs.2021.10.009</ArticleId><ArticleId IdType="pubmed">34924123</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada K., Hanayama Y., Yasuda M., Hasegawa K., Obika M., Kataoka H., Itoshima K., Okada K., Otsuka F. Clinical relevance of low androgen to gastroesophageal reflux symptoms. Endocr. J. 2018;65:1039&#x2013;1047. doi: 10.1507/endocrj.EJ18-0187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1507/endocrj.EJ18-0187</ArticleId><ArticleId IdType="pubmed">30068893</ArticleId></ArticleIdList></Reference><Reference><Citation>Takayama S., Namiki T., Odaguchi H., Arita R., Hisanaga A., Mitani K., Ito T. Prevention and Recovery of COVID-19 Patients With Kampo Medicine: Review of Case Reports and Ongoing Clinical Trials. Front. Pharmacol. 2021;12:656246. doi: 10.3389/fphar.2021.656246.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.656246</ArticleId><ArticleId IdType="pmc">PMC8261067</ArticleId><ArticleId IdType="pubmed">34248620</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaswa R., Govender I. Novel coronavirus pandemic: A clinical overview. S. Afr. Fam. Pract. 2020;62:e1&#x2013;e5. doi: 10.4102/safp.v62i1.5123.</Citation><ArticleIdList><ArticleId IdType="doi">10.4102/safp.v62i1.5123</ArticleId><ArticleId IdType="pmc">PMC8377866</ArticleId><ArticleId IdType="pubmed">32633997</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kessel S.A.M., Olde Hartman T.C., Lucassen P., van Jaarsveld C.H.M. Post-acute and long-COVID-19 symptoms in patients with mild diseases: A systematic review. Fam. Pract. 2022;39:159&#x2013;167. doi: 10.1093/fampra/cmab076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cmab076</ArticleId><ArticleId IdType="pmc">PMC8414057</ArticleId><ArticleId IdType="pubmed">34268556</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>